Determinants of Anti-S Immune Response at 12 Months after SARS-CoV-2 Vaccination in a Multicentric European Cohort of Healthcare Workers-ORCHESTRA Project.
COVID-19
antibody level
coronavirus
immunization
occupational health
serology
vaccine
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
26 Sep 2023
26 Sep 2023
Historique:
received:
02
08
2023
revised:
18
09
2023
accepted:
22
09
2023
medline:
28
10
2023
pubmed:
28
10
2023
entrez:
28
10
2023
Statut:
epublish
Résumé
The effectiveness of the immunity provided by SARS-CoV-2 vaccines is an important public health issue. We analyzed the determinants of 12-month serology in a multicenter European cohort of vaccinated healthcare workers (HCW). We analyzed the sociodemographic characteristics and levels of anti-SARS-CoV-2 spike antibodies (IgG) in a cohort of 16,101 vaccinated HCW from eleven centers in Germany, Italy, Romania, Slovakia and Spain. Considering the skewness of the distribution, the serological levels were transformed using log or cubic standardization and normalized by dividing them by center-specific standard errors. We fitted center-specific multivariate regression models to estimate the cohort-specific relative risks (RR) of an increase of one standard deviation of log or cubic antibody level and the corresponding 95% confidence interval (CI) for different factors and combined them in random-effects meta-analyses. We included 16,101 HCW in the analysis. A high antibody level was positively associated with age (RR = 1.04, 95% CI = 1.00-1.08 per 10-year increase), previous infection (RR = 1.78, 95% CI 1.29-2.45) and use of Spikevax [Moderna] with combinations compared to Comirnaty [BioNTech/Pfizer] (RR = 1.07, 95% CI 0.97-1.19) and was negatively associated with the time since last vaccine (RR = 0.94, 95% CI 0.91-0.98 per 30-day increase). These results provide insight about vaccine-induced immunity to SARS-CoV-2, an analysis of its determinants and quantification of the antibody decay trend with time since vaccination.
Sections du résumé
BACKGROUND
BACKGROUND
The effectiveness of the immunity provided by SARS-CoV-2 vaccines is an important public health issue. We analyzed the determinants of 12-month serology in a multicenter European cohort of vaccinated healthcare workers (HCW).
METHODS
METHODS
We analyzed the sociodemographic characteristics and levels of anti-SARS-CoV-2 spike antibodies (IgG) in a cohort of 16,101 vaccinated HCW from eleven centers in Germany, Italy, Romania, Slovakia and Spain. Considering the skewness of the distribution, the serological levels were transformed using log or cubic standardization and normalized by dividing them by center-specific standard errors. We fitted center-specific multivariate regression models to estimate the cohort-specific relative risks (RR) of an increase of one standard deviation of log or cubic antibody level and the corresponding 95% confidence interval (CI) for different factors and combined them in random-effects meta-analyses.
RESULTS
RESULTS
We included 16,101 HCW in the analysis. A high antibody level was positively associated with age (RR = 1.04, 95% CI = 1.00-1.08 per 10-year increase), previous infection (RR = 1.78, 95% CI 1.29-2.45) and use of Spikevax [Moderna] with combinations compared to Comirnaty [BioNTech/Pfizer] (RR = 1.07, 95% CI 0.97-1.19) and was negatively associated with the time since last vaccine (RR = 0.94, 95% CI 0.91-0.98 per 30-day increase).
CONCLUSIONS
CONCLUSIONS
These results provide insight about vaccine-induced immunity to SARS-CoV-2, an analysis of its determinants and quantification of the antibody decay trend with time since vaccination.
Identifiants
pubmed: 37896931
pii: vaccines11101527
doi: 10.3390/vaccines11101527
pmc: PMC10610704
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : EU Horizon 2020 research and innovation program, ORCHESTRA project
ID : 101016167
Références
Viruses. 2022 Nov 17;14(11):
pubmed: 36423150
Front Immunol. 2021 Nov 26;12:793953
pubmed: 34899762
NPJ Vaccines. 2022 Jan 27;7(1):14
pubmed: 35087066
Immunol Rev. 2022 Sep;310(1):27-46
pubmed: 35733376
Am J Epidemiol. 2021 Jan 4;190(1):161-175
pubmed: 32870978
Sci Rep. 2021 Nov 8;11(1):21601
pubmed: 34750399
Med Lav. 2022 Apr 26;113(2):e2022022
pubmed: 35481576
Nat Rev Immunol. 2021 Feb;21(2):73-82
pubmed: 33340022
Science. 2020 Sep 4;369(6508):
pubmed: 32669297
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Cell Host Microbe. 2022 Jan 12;30(1):97-109.e5
pubmed: 34953513
J Med Virol. 2020 May;92(5):512-517
pubmed: 32073157
Sci Rep. 2021 Mar 11;11(1):5788
pubmed: 33707646
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Science. 2021 Dec 03;374(6572):abm0829
pubmed: 34648302
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
Clin Microbiol Rev. 2019 Mar 13;32(2):
pubmed: 30867162
Lancet. 2022 Mar 5;399(10328):924-944
pubmed: 35202601
J Korean Med Sci. 2021 Nov 29;36(46):e311
pubmed: 34845875
EBioMedicine. 2021 Sep;71:103561
pubmed: 34455390
JAMA Intern Med. 2020 Oct 1;180(10):1356-1362
pubmed: 32808970
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Lancet. 2021 Sep 4;398(10303):856-869
pubmed: 34370971
Glob Health Med. 2023 Feb 28;5(1):5-14
pubmed: 36865900
Viruses. 2022 Nov 28;14(12):
pubmed: 36560660
Vaccines (Basel). 2023 Mar 28;11(4):
pubmed: 37112658
Hum Vaccin Immunother. 2021 Dec 02;17(12):4741-4746
pubmed: 34623224
N Engl J Med. 2022 Apr 7;386(14):1377-1380
pubmed: 35297591
Front Immunol. 2022 Aug 05;13:864278
pubmed: 35990623
Ir J Med Sci. 2022 Dec;191(6):2803-2811
pubmed: 35048229
Nat Immunol. 2022 Jun;23(6):940-946
pubmed: 35534723
Vaccine. 2022 May 3;40(20):2841-2847
pubmed: 35397946
Clin Microbiol Infect. 2012 Oct;18 Suppl 5:100-8
pubmed: 22862783
Front Immunol. 2022 Mar 28;13:786586
pubmed: 35418996
J Infect. 2021 Jul;83(1):e17-e18
pubmed: 33965428
Int J Mol Sci. 2022 Dec 06;23(23):
pubmed: 36499742
Vaccines (Basel). 2022 Dec 20;11(1):
pubmed: 36679853
mBio. 2022 Jun 28;13(3):e0018122
pubmed: 35475648
PLoS One. 2020 Dec 31;15(12):e0244126
pubmed: 33382764
Obesity (Silver Spring). 2022 May;30(5):999-1003
pubmed: 35226399
Front Immunol. 2022 Sep 29;13:986085
pubmed: 36248889
Clin Microbiol Infect. 2022 Feb;28(2):202-221
pubmed: 34715347
Nature. 2021 Jul;595(7867):426-431
pubmed: 34126625